GSK and Theravance initiate global Phase III study for chronic obstructive pulmonary drug

16 July 2014
gsk-location-big

UK pharma major GlaxoSmithKline (LSE: GSK) and its US partner Theravance (Nasdaq: THRX) have started a global Phase III study, known as IMPACT, which will evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COPD).

This is the first pivotal Phase III study in a program to evaluate a once-daily closesd triple combination treatment of an inhaled corticosteroid, a long-acting muscarninc antagonist and a long-acting beta-adrenergic agonist in patients with COPD.

A new pharmaceutical solution for respiratory diseases

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical